Novel hydrofluoroalkane suspension formulations for respiratory drug delivery

Bibliography

• PITTROFF M, JANNICK P: Solkane 227a pharma and solkane 134a pharma for use in medical sprays. Solvay Fluor. Newsletter (2004) 5.
   Google Scholar
• NAGEL MW, WIERSEMAN KJ, BATES L, MITCHELL JP: Performance of large and small volume valve holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler. J. Aero. Med. (2002) 15(4):427–433.
   Google Scholar
• DALBY RN, BYRON PR: Comparison of output particle size distributions form pressurised aerosols formulated as solutions or suspensions. Pharm. Res. (1988) 5(1):36–39.
   Google Scholar
• ZEIDLER M, CORREN J: Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat. Respir. Med. (2004) 3(1):35–44.
   Google Scholar
• WEERS JG, CLARK AR, CHALLONER P: High dose inhaled powder delivery: challenges and techniques. Proceedings of the 9th Respiratory Drug Delivery meeting. Palm Springs, CA, USA (2004).
   Google Scholar
• KOTSOKECHAGIA T, SMITH A, MILLER N, RADSPINNER D: The relationship between fine particle mass and drug concentration for high powder loading pressurised metered dose inhalers. Proceedings of 13th meeting of the Aerosol Society: Drug Delivery to the Lungs XIIL London, UK (2002).
   Google Scholar
• HARTMAN MS, GILL H, KENNEDY AA, TARARA T, WEERS J: The efficiency and stability of a novel lipid based budesonide metered dose inhaler formulation utilizing HFA. Proceedings of the Annual Meeting of the American Association of Pharmaceutical Scientists. Salt Lake City, UT, USA (2003).
   Google Scholar
• TARARA TE, HARTMAN MS, GILL H, KENNEDY AA, WEERS JG: Characterization of suspension based metered dose inhaler formulations composed of spray dried budesonide microcrystals dispersed in HFA 134a. Pharm. Res. (2004) 21(9):1607–1614.
   Google Scholar
• Cl-JAN HK, GONDA I: Development of a systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulized in polydisperse droplets. Int. J. Pharm. (1988) 41:147–157.
   Google Scholar
• •Theoretical framework to understand flocculation in aerosol droplets.
   Google Scholar
• VANBEVER R, MINTZES JD, WANG J et al.: Formulation and physical characterisation of large porous particles for inhalation. Pharm. Res. (1999) 16(11):1735–1742.
   Google Scholar
• DELLAMARY LA, TARARA TE, SMITH DJ et al.: Hollow porous particles in metered dose inhalers. Pharm. Res. (2000) 17(2):168–174.
   Google Scholar
• LEHMLER HJ, BUMMER PM, JAY M: Liquid ventilation - a new way to deliver drugs to diseased lungs. Chemtech. (199) 29(10):7–12.
   Google Scholar
• •A review of the potential application of HFA formulation to non-aerosol delivery.
   Google Scholar
• COURRIER HM, BUTZ N, VANDAMME TF: Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Therapeutic Drug Carrier Syst. (2002) 19(4&5):425–498.
   Google Scholar
• •Extensive analysis of the many ways of delivering therapeutic molecules via the lungs.
   Google Scholar
• JOHNSON KA: Interfacial phenomena and phase behaviour in metered does inhaler formulations. In: Lung Biology in Health and Disease (Volume 94). Inhalation Aerosols: Physical and Biological Basis for Therapy. AJ Hickey (Ed.), Marcel Dekker, New York (1996):385–415.
   Google Scholar
• •The reference book for a short introduction to colloidal theories applicable to HFA formulations.
   Google Scholar
• ISRAELACHVILI J: Intermolecular & surface forces. Academic Press (1997).
   Google Scholar
• SIDHU BK, WASHINGTON C, DAVIS SS, PUREWAL TS: Electrophoretic properties of lactose and salbutamol sulfate suspensions in halogenated solvents. Langmuir (1993) 9:839–843.
   Google Scholar
• WYATT DA, VINCENT B: Electrical effects in non-aqueous systems. J. Biop harm. Sci. (1992) 3(1/2):27–31.
   Google Scholar
• FOWKES FM, JINNAI H, MOSTAFA MA, ANDERSON FW, MOORE RJ: Mechanism of electric charging of particles in non-aqueous liquids. ACS Symposium Series (1982) 200:307–324.
   Google Scholar
• ROGUEDA P: Electrostatic Stabilisation of HFA pMDIs. Annual meeting of the American Association of Pharmaceutical Scientists. Denver, CO, USA (2001).
   Google Scholar
• ROGUEDA P: Particle interactions in HFA formulations: experiment, theory, and practice. Proceedings of the 8th Respiratory Drug Delivery Meeting. Tucson, AZ, USA (2002).
   Google Scholar
• ROGUEDA PG: HPFP, a model propellant for pMDIs. Drug Dev. Ind. Pharm. (2003) 29(1):29–50.
   Google Scholar
• JONES SA. MARTIN GP, FORBES B, BROAN MB: The influence of electrostatic stabilisation within apolar suspension formulations. 3Ist Annual Meeting d'-• Exposition of the Controlled Release Society. Honolulu, HI, USA (2004).
   Google Scholar
• GUPTA A, MYRDAL PB: Novel method for the determination of solubility in aerosol propellants. J. Pharm. Sci. (2004) 93(10):2411–2419.
   Google Scholar
• •A new method to study solubilisation in pressurised HFAs.
   Google Scholar
• WILLIAMS III RO, ROGERS TL, LIU J: Study of solubility of steroids in hydrofluoroalkane propellants. Drug Dev. Ind. Pharm. (1999) 25(12):1227–1234.
   Google Scholar
• GLOVER W, KWOK P, CHAN HK: Electrostatic charges in metered dose inhalers. Proceedings of the 9th Respiratory Drug Delivery meeting. Palm Springs, CA, USA (2004).
   Google Scholar
• GLOVER W. CT-JAN HK: Electrostatic charge characterization of pharmaceutical aerosols using electrical low-pressure impaction (ELPI). j Aero. Sci. (2004) 35(0:755–764.
   Google Scholar
• ORBAN JC, PEART J: Simultaneous electrostatic charge characterization and particle size analysis of metered dose inhalers (pMDIs) using the electrical low pressure impactor. Proceedings of the 9th Respiratory Drug Delivery meeting. Palm Springs, CA, USA (2004).
   Google Scholar
• ASHAYER R, LUCKHAM PF, MANIMAARAN S, ROGUEDA P: Investigation of the molecular interactions in a pMDI formulation by atomic force microscopy. Euro. J. Pharm. Sci. (2004) 21:533–543.
   Google Scholar
• MILLER NC: The effects of water in inhalation suspension aerosol formulations. Proceedings of the 1st Respiratory Drug Delivery meeting. Boca Raton, FL, USA (1990).
   Google Scholar
• BERRY J, KLINE LC, SHERWOOD JK et al.: Influence of the size of micronised active pharmaceutical ingredient on the aerodynamic particles size and stability of a metered does inhaler. Drug Dev. Ind. Pharm. (2004) 30(7):705–714.
   Google Scholar
• MALBREL CA, SOMASUNDARAN P: Water-induced dispersion flocculation of colloidal suspensions in nonpolar media. J. Coll Int. Sci. (1989) 133(2):404–408.
   Google Scholar
• GRIFFITHS P, PAUL k ROGUEDA P: Using polymers to control the stability of non-aqueous suspensions. Proceedings of the SCl/RSC Colloid Groups Meeting on Advances in Non-Aqueous Colloids: London, UK (2004).
   Google Scholar
• ROBERTS CJ: What can we learn from atomic force microscopy adhesion measurements with single drug particles? Eur. J. Pharm. Sci. (2004) 24:153–157.
   Google Scholar
• HOOTON JC, GERMAN CS, ALLEN S et al.: Characterisation of particle interactions by atomic force microscopy: Effect of contact area. Pharm. Res. (2003) 20(3):508–514.
   Google Scholar
• ROGUEDA P, GROSVENOR M, LUCKHAM P, MANIMAARAN S: Quantification of the interactions between micronised formoterol and a selection of surfaces found in a pressurised metered dose inhaler (pMDI). Proceedings of the Annual meeting of the American Association of Pharmaceutical Scientists. Salt Lake City, UT, USA (2003).
   Google Scholar
• ROGUEDA P, GROSVENOR M, LUCKHAM P, MANIMAARAN S: Evaluation of the effectiveness of stabilisers in reducing cohesive and adhesive forces between formoterol particles in pressurised metered dose inhalers (pMDIs). Proceedings of the Annual Meeting of the American Association of Pharmaceutical Scientists. Salt Lake City, UT, USA (2003).
   Google Scholar
• TRAINI D, ROGUEDA PGA, PRICE R: Interactions of model drugs in HFAs and crystals dissolution: an AFM in situ investigation using functionalised AFM probes. Proceedings of the 11th International Conference on Surface and Colloid Science. Iguassu Falls, Brazil (2003).
   Google Scholar
• TRAINI D, ROGUEDA P, YOUNG PM, PRICE R: Surface energy and interparticle forces correlations in model pMDI formulations. Pharm. Res. (2005) 22(5):816–825.
   Google Scholar
• •Introduction to a theory that predicts HFA suspension stability from particle surface properties.
   Google Scholar
• CLINE D, DALBY R: Predicting the quality of powders for inhalation from surface energy and area. Pharm. Res. (2002) 19(9):1274–1277.
   Google Scholar
• •Seminal paper that first attempted to link particle surface properties with delivery efficiency
   Google Scholar
• PHILLIPS EM, BYRON PR, DALBY RN: Axial ratio measurements for early detection of crystal growth in suspension type metered dose inhalers. Pharm. Res. (1993) 10(3):454–456.
   Google Scholar
• DALBY RN, PHILLIPS EM, BYRON PR: Determination of drug solubility in aerosol propellants. Pharm. Res. (1991) 8(9):1206–1209.
   Google Scholar
• VERVAET C, BYRON PR: Drug surfactant propellant interactions in HFA formulations. Int. J. Pharm. (1999) 186:13–30.
   Google Scholar
• BYRON PR, MILLER NC, BLONDINO FE, VISICH JE, WARD GH: Some aspects of alternative propellant solvency. Proceedings of the 4th Respiratory Drug Delivery meeting. Buffalo Grove, IL, USA (1994).
   Google Scholar
• DUMANLI I, LAROSA D, ZHU Y, ADJEI AL: An investigation of the solubility of recombinant human insulin in tetrafluorethane propellant and aqueous media. Proceedings of the 9th Respiratory Drug Delivery meeting. Palm Springs, FL, USA (2004).
   Google Scholar
• ROGUEDA PG, LUCKHAM PF, STEPHENS JS: Inhalation particles interactions in fluorinated liquids. Proceedings of Particles 2002. Orlando, USA (2002).
   Google Scholar
• YOUNG P, LEWIS D, TRAINI D: Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. J. Coll Int. Sci. (2003) 262:298–302.
   Google Scholar
• TRAINI D, ROGUEDA P, PRICE R, YOUNG PM: Assessing the Degree of Drug Adhesion to Different pMDI Canister Walls by Surface Energy and AFM Measurements. Proceedings of the 9th Respiratory Drug Delivery meeting. Palm Springs, USA (2004) RDDIX.
   Google Scholar
• WILLIAMS III RO, REPKA M, LIU J: Influence of propellant composition on drug delivery from a pressurized metered dose inhaler. Drug Dev. Ind. Pharm. (1998) 24(8):763–770.
   Google Scholar
• •A study of factors influencing HFA pMDIs delivery performance.
   Google Scholar
• MILLER NC, SCHULTZ RK, SCHACTNER WJ: Through life dose uniformity in pressurized metered dose inhalers. Proceedings of the Annual Meeting of the American Association of Pharmaceutical Scientists. Las Vegas, NV USA (1990).
   Google Scholar
• MILLER NC, SCHULTZ RK: Inter-particle interaction in nonpolar liquid media an its influence on dose reproducibility./ Biopharm. Sci. (1992) 3(1/2):19–25.
   Google Scholar
• GOVIND N, PRICE A, BRINDLEY A, SPARY S, COLTHORPE P: Correlation of two methods for assessing pMDI suspension stability. Proceedings of the 7th Respiratory Drug Delivery meeting. Tarpon Springs, FL, USA (2000).
   Google Scholar
• BERRY J, KLINE LC, HART JL, SEQUEIRA J: Influence of the storage orientation on the aerodynamic particle size of a suspension metered dose inhaler containing propellant HFA 227. Drug Dev. Ind. Pharm. (2003) 29(6):631–639.
   Google Scholar
• MICHAEL Y, SNOWDEN MJ, CHOWDHRY BZ, ASHURST IC, DAVIES-CUTTING CJ, RILEY T: Characterisation of the aggregation behaviour in salmeterol and fluticasone propionate inhalation aerosol system. Int. J. Pharm. (2001) 221:165–174.
   Google Scholar
• NELSON HS, CHAPMAN KR, PYKE SD, JOHNSON M, PRITCHARD JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunol (2003) 112(1):29–36.
   Google Scholar
• STEIN SW, STEFELY JS: Reinventing metered dose inhalers: from poorly efficient CFC MDIs to highly efficient HFA MDIs. www.drugdeliverytech.com (2003).
   Google Scholar
• ROGUEDA P: Pushing the boundaries: searching for novel HFA suspension formulations. Proceedings of the 9th Respiratory Drug Delivery meeting. Palm Springs, FL, USA (2004).
   Google Scholar
• BLONDINO FE, BYRON PR: Surfactant dissolution and water solubilisation in chlorine free liquefied gas propellants. Drug Dev. Ind. Pharm. (1998) 24(10935–945.
   Google Scholar
• BYRON PR, MILLER NC, BLONDINO FE, WISICH JE, WARD GH: Some aspects of alternative propellant solvency. Proceedings of the 4th Respiratory Drug Delivery meeting. Buffalo Grove, IL, USA (1994).
   Google Scholar
• DICKINSON PA, SEVILLE PC, McHALER H, PERKINS NC, TAYLOR G: An investigation of the solubility of various compounds in the hydrodluoroalkane propellants and possible model liquid propellants. J. Aero. Med. (2000) 13(3):179–186.
   Google Scholar
• GUPTA A, MYRDAL P: Evaluating solubility behaviour of compounds in HFA 134a propellant. Proceedings of the Annual Meeting of the American Association of Pharmaceutical Scientists. Baltimore, MD, USA (2004).
   Google Scholar
• METRANGOLO P, PILATI T, RESNATI G, STEVENAZZI A: Halogen bonding driven self assembly of fluorocarbons and hydrocarbons. Curr. Op. Coll Inter. Sci. (2003) 8:215–222.
   Google Scholar
• •Introduction to the concept of halogen bonding that may be applicable to HFA formulations.
   Google Scholar
• STEFELY JS: Novel Excipients for inhalation drug delivery: expanding the capability of the MDI. Drug. Del. Tech. (2002) 2(6):6–69.
   Google Scholar
• •An insight into the chemical structures that lead to polymer or surfactant solubility in HFAs.
   Google Scholar
• RIESS JG, KRAFFT MP: Fluorinated materials for in vivo oxygen transport (blood substitutes), diagnosis and drug delivery. Biomaterieds (1998) 19:1529–1539.
   Google Scholar
• KRAFFT MP: Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv. Drug Del. Rev. (2001) 47:209–228.
   Google Scholar
• GANDERTON D, LEWIS D, DAVIES R, MEAKIN B, CHURCH T: The formulation and evaluation of a CFC free budesonide pressurised metered dose inhaler. Resp. Med. (2003) (Supp. D):54–59.
   Google Scholar
• SASO Y, KONDO S, SEKI T, MORIMOTO K: Formulation design and pharmaceutical evaluation of an HFA 227 based furosemide metered dose inhaler. J. Drug Del. Sci. Tech. (2004) 14(2):135–140.
   Google Scholar
• PATEL N, FORBES B: The formulation of lipid: DNA complexes in pMDIs. King's College. Poster. J. Pharm. Pharmaco. (2003) 55(Supp.):541.
   Google Scholar
• GRIFFITHS PC, ROGUEDA P: Water induced phase separation in polymer/fluorinated liquid mixtures. Proceedings of the 11th International Conference on Surface and Colloid Science. Iguassu Falls, Brazil (2003).
   Google Scholar
• SMYTH HD: The influence of formulation variables on the performance of alternative propellant driven metered dose inhalers. Adv. Drug Del. Rev. (2003) 55:807–828.
   Google Scholar
• •An extensive review of factors influencing pMDI delivery.
   Google Scholar
• BRAMBILLA G, GANDERTON D, GARZIA R, LEWIS D, MEAKIN B, VENTURA P: Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int. J. Pharm. (1999) 186:53–61.
   Google Scholar
• STEIN SW, MYRDAL PB: A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. J. Pharm. Sci. (2004) 93(8):2158–2175.
   Google Scholar
• BEAUSANG EL, BURNS S, BUCKTON G: The engineering of powder surface energy to produce pMDI suspensions of improved stability. Proceedings of the Pharmaceutical Sciences World Congress. Kyoto, Japan (2004).
   Google Scholar
• BEAUSANG EL, BURNS S, BUCKTON G: Surface modification of a model hydrophilic drug using insoluble surfactants and the resulting effect on suspension behaviour in HFA 134a. Proceedings of 14th meeting of the Aerosol Society: Drug Delivery to the Lungs XIV London, UK (2003).
   Google Scholar
• URICANU V, EASTMAN JR, VINCENT B: Stability in colloidal mixtures containing particles with a large disparity in size. J. Coll Int. Sci. (2001) 233:1–11.
   Google Scholar
• BLEIER A, MATIJEVIC E: Heterocoagulation. J. Chem. Soc. Faraday Trans. (1978) 74: 1346–1359.
   Google Scholar
• JONES R, EVANS R, WARREN S, TAYLOR G: Development of a novel suspension MDI formulation using a low energy dispersion system. Proceedings of the 8th Respiratory Drug Delivery meeting. Tucson, AZ, USA (2002).
   Google Scholar
• JONES R, EVANS R, WARREN S, TAYLOR G: Development of a fluticasone propionate suspension pMDI formulation using a second particulate system. Proceedings of the 9th Respiratory Drug Delivery meeting. Palm Springs, CA, USA (2004).
   Google Scholar
• •Early mention of secondary particulate systems.
   Google Scholar
• FUEG LM, MULLER-WALZ R, NIEDERLAENDER C, VENTHOYE G: Flutiform HFA MDI: a stable fluticasone/ Formoterol combination employing Skyedry formulation technology. Proceedings of the 9th Respiratory Drug Delivery Meeting. Palm Springs, CA, USA (2004).
   Google Scholar
• STECKEL H, WHELE S: A novel formulation technique for metered dose inhaler (MDI) suspensions. Int. J. Pharm. (2004) 284:75–82.
   Google Scholar
• WILLIAMS III RO, ARRON MK, ALONSO MJ, REMUNAN-LOPEZ C: Investigation of a pMDI system containing chitosan microspheres and P134a. Int. J. Pharm. (1998) 174:209–222.
   Google Scholar
• COLUMBANO A, BUCKTON G, WIKELEY P: Characterisation of surface modified salbutamol sulphate-alkylpolyglycoside micropartilces prepared by spray drying. Int. J. Pharm. (2003) 253:61–70.
   Google Scholar
• REHMAN M, SHEKUNOVA BY, YORK P et al.: Optimisation of powders for pulmonary delivery using supercritical fluid technology. Euro. J. Pharm. Sci. (2004) 22(1):1–17.
   Google Scholar
• EDWARDS DA, AHNES J, CAPONETTI G et al.: Large porous particles for pulmonary drug delivery. Science (1997) 276:1868–1871.
   Google Scholar
• EDWARDS DA, BEN-JEBRIA A, LANGER R: Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Applied Physio. (1998) 84(2):379–385.
   Google Scholar
• HIRST PH, PITCARIN GR, WEERS JG et al.: In vivo lung deposition of hollow porous particles from a pressurised metered dose inhaler. Pharm. Res. (2002) 19(3):258–264.
   Google Scholar
• RABINOV BE: Nanosuspensions in drug delivery. Nat. Rev. (2004) 3:1–12.
   Google Scholar
• YIM D, CIPOLLA D, BOYD B: Feasability of pulmonary delivery of nano-suspension formulations using the AERx System. Proceedings of the 15th International Congress of the International Society for Aerosols in Medicine. Perth, Australia (2005).
   Google Scholar
• BIVAS-BENITA M, ROMEIJN S, JUNGINGER HE, BORCHARD G: PLGA-PEI naoparticles for gene delivery to pulmonary epithelium. Euro. J. Pharm. Biopharm. (2004) 58:1–6.
   Google Scholar
• CRAMPTON M, KINNERSLEY R, AYRES J: Sub-micrometer particle production by pressurised metered dose inhalers./ Aero. Med. (2004) 17(1):33–42.
   Google Scholar
• •Published evidence of the formation of nanodroplets by HFA pMDIs.
   Google Scholar
• JACOBS C, MULLER RH: Budesonide nanosuspension for pulmonary administration: Production and aerosolisation properties. Proceedings of the 28th Annual Meeting & Exposition of the Controlled Release of bioactive materials Society. San Diego, CA, USA (2001).
   Google Scholar
• BORM PJA, KREYLING W: Toxicologial hazards of inhaled nanoparticles - potential implications for drug delivery. J. Nanosci. Nanotech. (2004) 4(5):521–531.
   Google Scholar
• KEYLING WG, SEMMLE M, MOLLER W: Dosimetry and toxicology of ultrafine particles. J. Aero. Med. (2004) 17(2):140–152.
   Google Scholar
• PATEL N, MARLOW M, LAWRENCE MJ: Formation of fluorinated non-ionic surfactant microemulsions in hydrofluorocarbon 134a (HFC 124a). J. Coll Int. Sci. (2003) 258:345–353.
   Google Scholar
• LATTES A. RICO-LATTES I: Microemulsions of perfluorinated and semi fluorinated compounds. Art. Cells Blood Subs. Immob. Biotech. (1994) 22(4):1007–1018.
   Google Scholar
• WEERS JG, ARLAUSKAS RA, PELURA TJ: Characterisation of fluorocarbon in water emulsions with added triglyceride. Langmuir (2004) 20:7430–7435.
   Google Scholar
• STEYTLER DC, THORPE M, EASTOE J, DUPONT A, HEENAN RK: Microemulsion formation in 1,1,1,2 tetrafluoroethane (R134a). Langmuir (2003) 19:8715–8720.
   Google Scholar
• LAI CL, O'REAR EA, HARWELL JH: Formation of fluorocarbon surfactant reversed micelles in a halosolvent. j Coll Int. Sci. (1996) 183:166–175.
   Google Scholar
• •Self-aggregation phenomenon in fluorinated liquids as a mean to understand molecular interactions in HFAs.
   Google Scholar
• BUTZ N, PORTE C, COURRIER H, KRAFFT MP, VAN DAMME TF: Reverse water in fluorocarbon emulsions for use in pressurized metered dose inhalers containing hydrofluoroalkane propellants. Int. J. Pharm. (2002) 238:257–269.
   Google Scholar
• SOMMERVILLE ML, HICKEY AJ: Aerosol generation by metered dose inhalers containing dimethyl ether/propane inverse microemulsions. AAPS Phorm. Sci. Tech. (2003) 4(4):E58.
   Google Scholar
• RIESS JG, KRAFFT MP: Advanced fluorocarbon based systems for oxygen and drug delivery, and diagnosis. Art. Cells Blood Subs. Immob. Biotech. (1997) 25(1&2):43–52.
   Google Scholar
• •Extensive review of HFA formulations.
   Google Scholar
• BYRON PR: Aerosol formulation, generation and delivery using metered systems. Proceedings of the 1st Respiratory Drug Delivery meeting. Boca Raton, FL, USA (1990).
   Google Scholar